NVS
Pharma

FDA grants full approval to Novartis' Fabhalta in IgAN

The FDA has converted its accelerated approval for Novartis' Fabhalta to a full blessing to treat patients with immunoglobulin A nephropathy.
Kevin Dunleavy Jul 17, 2026 11:33am
Magnifying glass with pills on blue

Regulatory tracker: Boehringer's Jascayd wins nod in Europe

Jul 17, 2026 11:20am
9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experience

9 of the Top 10 Pharma Manufacturers Choose Redi Health

Brought to you by Redi Health
FDA

Novo, Alvotech written up after FDA site inspections

Jul 17, 2026 10:56am
Clinical Success Is No Longer One Number

Clinical Success Is No Longer One Number

Brought to you by Intelligencia AI
showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Lilly’s Foundayo scripts tick up

Jul 17, 2026 10:30am
More News

GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia

Jul 17, 2026 9:38am

Foundation Medicine starts push to stand out in cancer testing

Jul 17, 2026 3:41am

CG Life film festival gives rare diseases a starring role

Jul 16, 2026 5:00pm

Huahai poaches quality chief from Hengrui amid FDA citations

Jul 16, 2026 4:11pm